How Do Labeling Claims and the Evidence Chain Correspond in Overseas Medical Device Registration?

Answer: In overseas medical device registration, labeling claims must correspond strictly to the evidence chain in the registration dossier. Companies should first determine the product's regulatory classification and registration pathway in the target country, then support claims on functionality, performance, indications, warnings, and contraindications with the technical file, risk management report, clinical evaluation, or performance verification data. Common risks include claims that exceed the approved registration scope, reference outdated standards, or rely on incomplete clinical evidence. Companies should establish a cross-reference table from the draft label to the registration submission documents so that each claim is supported by a corresponding document, such as a test report, clinical literature, or ISO 10993 biocompatibility report.

Published: 2026-07-10 21:51 | Updated: 2026-07-10 21:51

Key Summary

In overseas medical device registration, labeling claims must be strictly aligned with the evidence chain in the registration materials. Companies should first determine the product's regulatory classification and registration pathway in the target country, then support claims on function, performance, indications, and other label statements with the technical file, risk management report, clinical evaluation, or performance verification data. Common risks include claims beyond the approved registration scope, references to expired standards, and incomplete clinical evidence. Companies need to establish a cross-reference table from the draft label to the registration submission documents, ensuring that every claim has corresponding supporting documentation, such as test reports, clinical literature, or ISO 10993 biocompatibility reports.

For GHWP member states, Southeast Asia, the Middle East, and other markets, companies may reuse core technical documents from NMPA, CE, or FDA submissions, but must complete localization conversion, including language, units, standard differences, and local regulatory requirements. The local agent or authorized representative is responsible for verifying label compliance with the registration certificate and monitoring post-market changes. The company's registration dossier should include draft labels, a claim basis list, risk management documents, clinical evaluation report summaries, quality management system certificates such as ISO 13485 and MDSAP, and local agent authorization documents. Common errors to avoid include claims inconsistent with the registration certificate scope, use of unapproved indications, labeling translation errors, and omission of required symbols. Companies are advised to complete a claim-to-evidence mapping table before registration starts and use it as an internal review tool.

Compiled based on the Aimeili regulatory practice question bank, the medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country regulator and the product data foundation.

Applicable Scenarios and Core Questions

During overseas medical device registration, labeling claims, including product name, intended use, performance indicators, contraindications, and warnings, must be strictly consistent with the evidence chain in the registration submission. Inconsistency may lead to registration corrections, deficiency letters, or even rejection. This guide applies to companies submitting registrations to GHWP member states such as China, Japan, South Korea, and Southeast Asian countries, as well as markets in the Middle East and Latin America. Core questions include: Which claims require evidence? What form and level of evidence is required? How should the correspondence be established and maintained? What is the role of the local agent?

A common misconception among companies is to directly translate and use domestic registration labels while ignoring target-country-specific evidence requirements. For example, some countries require clinical evaluation to be conducted in the local population, or accept international standards with national deviations. Therefore, during registration planning, the supporting source and document number for each claim should be clarified.

Registration Decision Logic

Step 1: Determine whether the product falls within the target country's medical device regulatory scope. Some functional products may not be considered medical devices locally but may instead be regulated as cosmetics or health devices, in which case labeling requirements differ.

Step 2: Determine the registration pathway based on product risk class. For example, ASEAN countries may use self-declaration or approval depending on classification. Singapore requires technical file review of labels and instructions for Class II and above products.

Step 3: Assess whether existing documents, such as an NMPA registration certificate, CE technical file, FDA 510(k), ISO 13485 certificate, or MDSAP audit report, can be used directly or require adjustment. For example, a CE clinical evaluation report citing European epidemiological data may not be accepted in Latin America.

Step 4: Confirm what requires localization conversion: language, such as Portuguese for Brazil; units of measure; standard versions, such as differences among IEC 60601 series versions; and special local regulatory marks, such as the Medical Device Authority mark in Malaysia.

Step 5: Establish a claim-to-evidence mapping table that corresponds item by item to the registration dossier checklist. Every sentence of label text should be traceable to a test report, risk management document, clinical evaluation report, or standard reference.

Documents and Evidence

Documents that must be prepared include:

• Draft product labels, including claims in packaging, instructions for use, and promotional materials
• Labeling claim basis list in table form, listing each claim and the corresponding evidence document name, version, and section
• Technical file, including performance verification reports, software validation reports, and sterilization validation reports
• Risk management report under ISO 14971, including risk control measures corresponding to label warnings
• Clinical evaluation report or clinical evidence, if applicable, including literature review, clinical trial summary, and PMCF plan
• Quality management system certificate, such as ISO 13485; MDSAP certificates may be used for multi-country recognition
• Local agent authorization documents, including power of attorney and evidence of agent qualifications
• Post-market surveillance plan, including the label update process

In evidence chain management, version control is recommended. Any label modification must trigger an update review of the corresponding evidence documents. For example, changing an indication from 'treatment of pain' to 'relief of chronic pain' requires confirmation that the clinical report covers this scope.

Common Errors

• Claims exceeding the approved registration scope: for example, using 'sterile' when sterilization validation applies only to a specific packaging configuration and does not cover all configurations.
• Citing outdated standards: for example, the label states 'complies with ISO 14971:2007' while registration requires the 2019 version.
• Insufficient clinical evidence: claiming 'reduces infection rate' with only in vitro data and no human clinical data.
• Translation errors causing ambiguity: for example, mistranslating 'contraindicated' as 'contraindication' without specifying the population.
• Omitting mandatory information: for example, Brazil requires display of the ANVISA registration number, and India requires a 'non-sterile' mark.
• Failure to consider multi-country registration differences: the same product may have different label content in different countries, but the company has not established a unified internal baseline.

Corporate Preparation Checklist

• Form a cross-functional team covering regulatory affairs, quality, R&D, and marketing, and clarify label review responsibilities.
• Collect target country labeling regulations and guidance, such as IMDRF labeling guidance and local food and drug authority requirements.
• Create a labeling claim and evidence mapping table template, assigning a unique number to each claim.
• Review the validity period and scope of application of existing evidence documents.
• Complete localization translation and have it proofread by a native-language regulatory professional.
• Have the local agent or authorized representative confirm that the label meets local requirements.
• Establish a change control procedure: any label modification must trigger a review of evidence documents.
• Retain all versions of labels and evidence documents for inspection.

Aimeili Perspective

From a regulatory consultancy perspective, the easiest misjudgment for companies is underestimating the strictness of the evidence chain and assuming that a domestic registration certificate or CE certificate allows direct label transfer. In reality, each target country has an independent regulatory system, and claims must be specific to what that country has approved for registration. It is advisable to complete a target-country regulatory gap analysis early in the project to clarify which documents can be reused, such as ISO 13485 certificates and basic performance test reports, and which must be localized, such as clinical evaluation, language, standard versions, and agent documents.

A local agent is not merely an intermediary that transmits documents; it should also participate in label review, because it bears direct responsibility for the consequences of local non-compliance. Certificate control, such as whether the registration certificate holder is the company itself, is critical, as a change of agent may affect certificate validity. For multi-country registration, establishing a unified core technical file library and preparing label addendum documents for country-specific differences can significantly reduce duplicate preparation and deficiency response risks. Remember: the evidence chain is not something to be supplemented after the fact; it is the cornerstone before registration begins.

Common Follow-Up Questions

Can labeling claims cite literature instead of internal test reports?

Yes, but the literature must undergo systematic evaluation and be relevant to the product characteristics. The target country may require literature derived from the local population or of a high evidence level. It is advisable to prioritize internal test data; when citing literature, provide the search strategy, screening criteria, and full text for review.

Does a label update require re-registration?

It depends on the extent of the change. Minor changes, such as font or layout, usually only require notifying the agent; major changes, such as indications, warnings, or contraindications, may require a supplement or re-registration. Each country has different rules; for example, Thailand requires prior approval for label changes, while the Philippines allows filing. Companies should establish a change classification matrix.

How can label versions be managed uniformly across multiple countries?

A 'core label + country addendum' model can be adopted. The core label contains general information, such as product name, model, manufacturer, and general warnings, while country addenda contain locally specific information, such as registration number, agent information, and language requirements. Each country has one version, but the core part is globally consistent, reducing verification workload. It is recommended to use label management software to record version history and approval records.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities often examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the scope of the ISO 13485 certificate does not match the declared product, or if the manufacturing address, model specifications, or instructions version is inconsistent with the test report, the company may be asked for supplementary explanation even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions version, and quality system certificate item by item. This action appears basic but can significantly reduce the probability of deficiencies, especially for projects submitted simultaneously to multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve local agents, authorized representatives, importers, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already hold CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; subsequently, when there is a manufacturing address change, model expansion, instructions update, or agent change, the certificate may become disconnected from market sales.

Aimeili recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of doing so is not only to improve registration efficiency in a single country, but more importantly to help companies build replicable overseas compliance capabilities and reduce the cost of starting document preparation from scratch each time they enter a new market.

Continue Reading

Previous: What Should Be Done When Quality System Evidence Is Inconsistent in Overseas Medical Device Registration?

Next: What Is the Difference Between Importer and Distributor Responsibilities in Overseas Medical Device Registration?

Recommended reading:

• How Should Technical Documentation for Software Medical Device Overseas Registration Be Prepared?
• How Should Registration Dossiers Be Planned Uniformly for Southeast Asia Medical Device Registration?
• What Are the Risks of Local Agents in Middle East Medical Device Registration?
• Why Are Latin America Medical Device Registration Timelines Easily Extended?
• How Should Product Classification Be Determined for Overseas Medical Device Registration?

Return to FAQ Center | News | Contact Aimeili

Content Review and Applicability Boundary

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supplementary judgment.

Applicability boundary: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements, testing conclusions, or legal opinions of the target country regulatory authority.